Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 311 194 M
EBIT 2018 260 000 M
Net income 2018 203 782 M
Finance 2018 535 403 M
Yield 2018 2,53%
Sales 2019 1 319 004 M
EBIT 2019 249 000 M
Net income 2019 203 075 M
Finance 2019 645 271 M
Yield 2019 2,63%
P/E ratio 2018 14,24
P/E ratio 2019 14,25
EV / Sales2018 1,91x
EV / Sales2019 1,81x
Capitalization 3 035 814 M
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
Sector
Pharmaceuticals
Calendar
06/02Presentation
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
05/25 ASTELLAS PHARMA : Announces Record Number of Abstracts Highlighting Breadth and ..
05/19 ASTELLAS PHARMA : MSD submits application for approval of type-2 diabetes drug c..
05/18 ASTELLAS PHARMA : Data on Pain Reported by Researchers at Astellas Pharma (Effec..
05/18 ASTELLAS PHARMA : Announces Decision to Discontinue ASP8273 Treatment and Close ..
05/18 NANOSTRING TECHNOLOGIES, INC. (NASDA : NSTG) Files An 8-K Other Events
05/15 ASTELLAS PHARMA : Announces Continuation of Performance-linked Stock Compensatio..
05/12 ASTELLAS PHARMA : Announces Decision to Discontinue ASP8273 Treatment and Close ..
05/11 ASTELLAS PHARMA : The Institute of Medical Science, the University of Tokyo, and..
05/01 TRANSFER OF 16 LONG-LISTED PRODUCTS : Closing of Asset Purchase Agreement
04/28 TRANSFER OF 16 LONG-LISTED PRODUCTS : Closing of Asset Purchase Agreement
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/26Great Place To Work And Fortune Name Astellas To Inaugural Best Workplaces In.. 
05/20Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fun..
1
05/20Astellas completes 800 million euro biotech acquisition of Ogeda: Pharma Time.. 
05/19Astellas completes 800 million euro biotech acquisition
3
05/18NanoString revises guidance after Astellas and Pfizer ax late-stage study of .. 
More tweets
Qtime:16
News from SeekingAlpha
05/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 19, 2017
05/18 NanoString revises guidance after Astellas and Pfizer ax late-stage study of ..
05/15 Cytokinetics' CK-2127107 an Orphan Drug for spinal muscular atrophy
05/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 12, 2017
05/11 Astellas bails on late-stage lung cancer candidate ASP8273
Advertisement
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 1 623  JPY
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-13.28%27 253
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results